

October 30, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Clarification on Significant Volume Movement in Company's Shares
Ref: Email Reference No. L/SURV/ONL/PV/AA/ 2025-2026 / 629 received from BSE on October 30, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to your Email communication dated October 30, 2025 with subject – Volume Movement Letter, we submit the following:

The Company has been making timely and adequate disclosures of all material events and information to the Exchanges, in strict compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The recent increase in the trading volume of the Company's securities appears to be purely market driven. We confirm that there is no other information/announcement as on date (including any pending announcement) which, in the opinion of the Company, may have a bearing on the price/volume movement of its securities.

We maintain continuous compliance with the disclosure obligations as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to kindly take the above information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.